Clobecort Cream

Inflammatory skin disorders, Eczema, dermatitis, atopic eczema, photodermatitis, otitis externa, primary irritant & allergic dermatitis (napkin rash), prurigo nodularis, seborrhoeic dermatitis, insect bite reactions.

Wash hands and dry them Squeeze out the correct amount of cream onto index finger. Half a fingertip will cover a patchnof skin the same size as the palm of hand. Gently rub the cream into the skin area that are treating. Wash hands again (unless it is your hands you are treating).

Topical/Cutaneous Corticosteroid-responsive dermatoses Adult: Use as 0.05% cream or ointment to be applied thinly once or bid on affected areas. This medicine should not be used every day for more than 4 weeks at a time.

Pregnancy (in high doses). Presence of acute infections. Treatment of rosacea; leg ulcers; acne vulgaris; widespread plaque psoriasis. Child <1 yr.

Clobetasone butyrate is classed as a moderately potent topical corticosteroid. Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; and reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation.

May be absorbed in sufficient amounts to cause systemic effects when applied topically to large areas, broken skin or under occlusive dressings. Peptic ulcer, osteoporosis, psychoses or severe psychoneuroses. Not to be used indiscriminately for pruritus. CHF or hypertension. Diabetes mellitus, epilepsy, glaucoma, infectious diseases, ocular herpes simplex, chronic renal failure and uraemia. Active or doubtfully quiescent tuberculosis. Local treatment of eye disorders. Elderly. Prolonged use on the face.

Local atrophic changes; pigmentation changes & hypertrichosis. Increased liability to infection. Infections may be masked. Acute adrenal insufficiency. Growth retardation in child. Cushingoid symptoms. Amenorrhoea, hyperhidrosis, skin thinning,

Pregnancy Safety data on clobetasol in pregnant woman is not available Published data report a significantly increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy Advise pregnant women of the potential risk to a fetus and to use clobetasol on the smallest area of skin and for the shortest duration possible In animal reproduction studies, increased malformations (eg, cleft palate and skeletal abnormalities), were observed after SC administration of clobetasol to pregnant mice and rabbits Lactation No information is available regarding the presence of clobetasol in breast milk or its effects on the breastfed infant or on milk production Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects Unknown whether topical administration of clobetasol could result in sufficient systemic absorption to produce detectable quantities in human milk To minimize potential exposure to the breastfed infant via breast milk, use clobetasol on the smallest area of skin and for the shortest duration possible while breastfeeding Advise breastfeeding women to avoid applying clobetasol directly to the nipple and areola to prevent direct infant exposure